endocrine system - weebly
TRANSCRIPT
![Page 1: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/1.jpg)
Endocrine System
KNH 406
![Page 2: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/2.jpg)
Diabetes Mellitus
7% of population; 1/3 undiagnosed
$132 billion in health care
Sixth leading cause of death
Complications of diabetes (DM)
![Page 3: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/3.jpg)
![Page 4: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/4.jpg)
![Page 5: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/5.jpg)
Diabetes Mellitus
Group of disorders
Defects in insulin production, action, or both
Results in glucose intolerance
Long-term damage correlated with failure of eyes,
kidneys, nerves, heart, blood vessels
![Page 6: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/6.jpg)
Diabetes Mellitus
Managed by health care team
Treatment individualized for patient and family
Diabetes Self Management Education (DSME) vital
element of care
![Page 7: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/7.jpg)
Type 1 DM
5-10% of diagnosed cases
Immune mediated – cellular-mediated autoimmune
destruction of beta cells
Ideopathic
![Page 8: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/8.jpg)
Type 1 DM
Pathophys/clinical manifestations
Inability of cells to use glucose for energy
Hyperglycemia and cells starve
Polyuria
Polydipsia
Polyphagia
![Page 9: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/9.jpg)
Type 1 DM
Pathophys/clinical manifestations
Lipolysis
Fatty acids transformed to ketones
pH falls
Ketosuria
Metabolic acidosis/ ketoacidosis
![Page 10: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/10.jpg)
Type 1 DM
Pathophys/clinical manifestations
Hypovolemia
Potassium, sodium, magnesium, phosphorus lost
Decreased Hg, Hct, protein, WBC, creatinine, serum osmolality
Weight loss
Hypovolemic shock
Deep, labored breathing
![Page 11: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/11.jpg)
© 2007 Thomson - Wadsworth
![Page 12: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/12.jpg)
Type 1 DM
Diabetic Ketoacidosis (DKA)
Dehydration
Electrolyte imbalances
Hyperglycemia
h
![Page 13: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/13.jpg)
Type 1 DM
DKA -Treatment
Administration of IV fluids, insulin, electrolytes
Risk for micro- and macrovascular complications
Increased morbidity and mortality
![Page 14: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/14.jpg)
Type 1 DM
Macrovascular complications
CVD – 65% of deaths
Coexistence of hypertension & dyslipidemia
Underlying metabolic syndrome
Treat hypertension and lipids
![Page 15: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/15.jpg)
Type 1 DM
Microvascular complications
Nephropathy
Retinopathy
Neuropathy
![Page 16: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/16.jpg)
Type 1 DM
Nephropathy - treatment
May be delayed by intensive diabetes management
Protein restriction
ACE inhibitors
Kidney failure treatment – dialysis or transplant
![Page 17: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/17.jpg)
Type 1 DM
Retinopathy
Most frequent cause of new blindness
Associated with duration of DM
Likely if nephropathy present
Macular edema d/t hypertension
glaucoma & cataracts
Progression slowed with glycemic and BP control
![Page 18: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/18.jpg)
Type 1 DM Neuropathy
Autonomic and peripheral
GI, genitourinary tract, CV system
Gastroparesis, delayed gastric emptying, vagus nerve damage affecting peristalsis
Constipation alternates with diarrhea
Bladder and/or sexual dysfunction
Recurrent UTIs
Resting tachycardia
Orthostatic hypotension
Silent heart disease
![Page 19: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/19.jpg)
Type 1 DM Diagnosis/ lab measures
Casual plasma glucose ≥ 200 mg/dL + symptoms
Fasting plasma glucose ≥ 126 mg/dL
2 hr. postprandial glucose 140-199 mg/dL – OGTT
![Page 20: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/20.jpg)
Type 1 DM Measures of Glycemic Control
Self-monitoring of blood glucose and A1C
Recommended A1C and plasma glucose goal
Frequency and recommendations
![Page 21: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/21.jpg)
![Page 22: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/22.jpg)
© 2007 Thomson - Wadsworth
![Page 23: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/23.jpg)
Type 1 DM Measures of Glycemic Control
Glycated Hemoglobin (A1C)
Higher glucose
Avg. concentration previous 2-4 mo.
Not recommended for dg of DM
Measured at least 2X per year
Inappropriate for pt. with anemias
![Page 24: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/24.jpg)
Type 1 DM Measures of Glycemic Control
SMBG
Drop of blood via finger prick
3 or more times daily
Assists in adjustment for eating and medication patterns
Identifies food, exercise, other patterns that affect glycemic
control
![Page 25: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/25.jpg)
Type 1 DM Measures of Glycemic Control
Fructosoamine
Glycemic control over 1-3 wk. period
Not reliable with renal or liver disease
Urine testing for glucose
Renal threshold - glucose > 250
Urine testing for ketones
Should be tested when glucose > 300
![Page 26: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/26.jpg)
Type 1 DM Treatment
risk factors
Daily exogenous insulin
Nutrition therapy
Exercise
![Page 27: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/27.jpg)
Type 1 DM Treatment - Types of Insulin
Meant to mimic normal physiological action of insulin
Classified based on onset of action, peak time, duration of
action
Dosage typically based on body weight, adjusted based on
blood glucose levels
![Page 28: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/28.jpg)
![Page 29: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/29.jpg)
![Page 30: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/30.jpg)
Type 1 DM Treatment - Insulin Regimens
Fixed/conventional/standard
Flexible/intensive
Continuous infusion (CSII)
![Page 31: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/31.jpg)
Type 1 DM Treatment - Insulin Regimens
Fixed/conventional/standard
Constant dose of basal insulin
With short or rapid (bolus) insulin
“Mixed dose” or split mixed dose
Must synchronize insulin with food intake
![Page 32: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/32.jpg)
Type 1 DM Treatment - Insulin Regimens
Flexible
Multiple daily injections
Bolus insulin before meals
Basal insulin once or twice daily
More flexibility
![Page 33: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/33.jpg)
Type 1 DM Treatment - Insulin Regimens
Continuous infusion
Basal rapid or short
Boluses are given before meals
![Page 34: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/34.jpg)
Type 1 DM Insulin Regimens
Syringes or pens
Syringes disposable - U-100 insulin
Pens refillable - 150-300 U insulin
Insulin pumps
Powered by battery
Inhaled insulin
FDA approved Jan. 2006 – Exubera
Short acting
![Page 35: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/35.jpg)
![Page 36: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/36.jpg)
Type 1 DM Insulin – side effects
Hypoglycemia
Loss of consciousness, confusion
Treatment:
Mild
Severe
Weight gain
Lipohypertrophy at site of injection
Drugs that alter effect
![Page 37: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/37.jpg)
Type 1 DM Physical activity
Benefits far exceed risks
Can cause hypoglycemia or hyperglycemia
Monitor blood glucose before and after
Make appropriate adjustments for CHO and insulin
Moderate exercise < 30 min. – likely no adjustment
![Page 38: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/38.jpg)
Type 1 DM Nutrition Therapy
Should be individualized!
Based on:
Self care treatment plan
Learning ability
Current lifestyle
![Page 39: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/39.jpg)
Type 1 DM
Nutrition Therapy
CHO
Alcohol kcal considered additional
Meal planning
Individualized
![Page 40: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/40.jpg)
Type 1 DM
Nutrition therapy
Carbohydrate counting
Consistent amount of CHO at meals and snacks
Count starches, fruits, milk/yogurt, sweets
Count amount of food containing 15 g CHO or
Total grams of CHO
3 skill levels
![Page 41: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/41.jpg)
Type 1 DM
Nutrition therapy
Exchange System
Exchange Lists for Meal Planning
Substitution of different foods with each of 3 groups
Each food on particular list can be substituted with food on
same list
![Page 42: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/42.jpg)
Type 1 DM
Short-term illness
Supplemental insulin
Replacement fluids
Electrolytes
Glucose
SMBG
Urine testing
Prevent progression
Less than 24 hrs.
![Page 43: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/43.jpg)
Type 2 DM
90-95% of diagnosed cases
Adults, elderly, persons of color
Increased risk traits
![Page 44: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/44.jpg)
![Page 45: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/45.jpg)
Type 2 DM
Etiology
Heredity
Obesity
Physical inactivity
High or low birth weight
Poor placental growth
![Page 46: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/46.jpg)
Type 2 DM
Pathophysiology
Insulin resistance
Pancreas increases production
Pancreas stops producing insulin
Insulin deficiency
Glucose intolerance
DM develops in obese
Hyperglycemia develops
![Page 47: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/47.jpg)
Type 2 DM
Metabolic syndrome
Central obesity
Insulin resistance
Dyslipidemia
Hypertension
![Page 48: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/48.jpg)
Type 2 DM
Clinical Manifestations
Insidious
Criteria for testing based on risk factors including PCOS
Disease may progress
![Page 49: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/49.jpg)
Type 2 DM
Hyperglycemic Hyperosmolar Nonketotic
Syndrome (HHNS)
Blood glucose ≥ 600 mg/dL
Infection
Dehydration
Symptoms
Treatment
![Page 50: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/50.jpg)
Type 2 DM Treatment
Glycemic control depends on:
Hepatic glucose production
Glucose uptake by periphery
Absorption of glucose from food
Nutrition therapy
Physical activity
Medications
![Page 51: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/51.jpg)
Type 2 DM Treatment - medications
Seven classes
Alpha-glucosidase inhibitors (AGIs)
Amylin analogs
Biguanides
Incretin mimetics
Meglitinides
Sulfonylurea agents
Thiazolidinediones
Consider drug-nutrient interactions
![Page 52: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/52.jpg)
Type 2 DM Physical Activity
Prescribed for all
Enhances blood glucose uptake
Enhances weight loss efforts
30-45 min. 3-5 days/week, no more than 2 consecutive days of rest
Adjust CHO and insulin
Consider CHO snack pre & post exercise
![Page 53: Endocrine System - Weebly](https://reader034.vdocuments.site/reader034/viewer/2022042705/626635e938bfe5577e40a23d/html5/thumbnails/53.jpg)
Type 2 DM Nutrition Therapy
Plan based on metabolic priorities
Lifestyle and behavior modification
Weight management
Monitor total CHO
< 20% pro.
Dietary fat goals for CVD
14 grams fiber/1000 kcal